Major depression among methamphetamine users entering drug treatment programs

Medical Journal of Australia

Volumn 195, Issue 3 SUPPL., 2011, Pages

  McKetin, Rebecca ^a,b   Lubman, Daniel I ^c,d   Lee, Nicole M ^e   Ross, Joanne E ^b   Slade, Tim N ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c TURNING POINT ALCOHOL AND DRUG CENTRE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CANNABIS; COCAINE; DIAMORPHINE; METHAMPHETAMINE; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH; PATIENT COUNSELING; PREVALENCE; PSYCHIATRIC DIAGNOSIS; REHABILITATION; SHORT FORM 12; SUICIDAL IDEATION; SYMPTOMATOLOGY;

EID: 79961061754     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2011.tb03266.x     Document Type: Article

References (18)

1. Riehman KS, Iguchi MY, Anglin MD. Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment. Psychol Addict Behav 2002; 16: 333-337.
2. Rawson RA, Gonzales R, Brethen R. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 2002; 23: 145-150.
3. Hasin D, Nunes EV, Meydan J. Comorbidity of alcohol, drug, and psychiatric disorders: epidemiology. In: Kranzler HR, Tinsley JA, editors. Dual diagnosis and psychiatric treatment: substance abuse and comorbid disorders. 2nd ed. New York: Marcel Dekker, 2004: 1-34.
4. Bamford NS, Zhang H, Joyce JA, et al. Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron 2008; 58: 89-103.
5. London ED, Simon SL, Berman SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 2004; 61: 73-84.
6. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, et al. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis 2009; 197: 225-231.
7. Baker A, Lee NK, Claire M, et al. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction 2005; 100: 367-378.
8. Janca A, Robins LN, Cottler LB, et al. Clinical observation of assessment using the Composite International Diagnostic Interview (CIDI). An analysis of the CIDI Field Trials - Wave II at the St Louis site. Br J Psychiatry 1992; 160: 815-818.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: APA, 2000.
10. Haro JM, Arbabzadeh-Bouchez S, Brugha TS, et al. Concordance of the Composite International Diagnostic Interview version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO world mental health surveys. Int J Methods Psychiatr Res 2006; 15: 167-180.
11. Darke S, Hall W, Wodak A, et al. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992; 87: 733-742.
12. Ware JE, Kosinksi MM, Keller SD. How to score the SF-12 physical and mental health summary scales. Boston: The Health Institute, New England Medical Centre, 1995.
13. McKetin R, Kelly E, Indig D. Characteristics of treatment provided for amphetamine use in New South Wales, Australia. Drug Alcohol Rev 2005; 24: 433-436.
14. Hasin D, Samet S, Nunes E, et al. Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 2006; 163: 689-696.
15. Kranzler HR, Kadden RM, Babor TF, et al. Validity of the SCID in substance abuse patients. Addiction 1996; 91: 859-868.
16. Bryant KJ, Rounsaville B, Spitzer RL, et al. Reliability of dual diagnosis. Substance dependence and psychiatric disorders. J Nerv Ment Dis 1992; 180: 251-257.
17. McGregor C, Srisurapanont M, Jittiwutikarn J, et al. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005; 100: 1320-1329.
18. De Rudolf GM. The treatment of depression with methylamphetamine. J Ment Sci 1956; 102: 358-363